Search

Your search keyword '"Pessoa, Rodrigo Rodrigues"' showing total 31 results
Start Over Author "Pessoa, Rodrigo Rodrigues"
31 results on '"Pessoa, Rodrigo Rodrigues"'

7. Reply by Authors

Author

Rodriguez-Homs, Miguel, Pessoa, Rodrigo Rodrigues, Konety, Badrinath, Gershman, Boris, Clark, Peter E., Bronsert, Michael, Flaig, Thomas W., Tevis, Sarah E., Lloyd, Granville, Morrison, Jeffrey C., and Kim, Simon P.

Published
2022
Full Text
View/download PDF

10. VALUE OF B7-H3 EXPRESSION AS A PREDICTOR OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN UROTHELIAL CELL CARCINOMA OF BLADDER

Author

Nabavizadeh, Reza, primary, Pessoa, Rodrigo Rodrigues, additional, Dumbrava, Mihai, additional, Horjeti, Edlira, additional, Mahmoud, Ahmed M, additional, Mueller, Brenda, additional, Thapa, Prabin, additional, Boorjian, Stephen A, additional, Cheville, John, additional, Dong, Haidong, additional, Frank, Igor, additional, and Lucien, Fabrice, additional

Published
2024
Full Text
View/download PDF

11. The Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell Carcinoma

Author

Pessoa, Rodrigo Rodrigues, primary, Nabavizadeh, Reza, additional, Quevedo, Fernando, additional, Joyce, Daniel D., additional, Lohse, Christine M., additional, Sharma, Vidit, additional, Costello, Brian A., additional, Boorjian, Stephen A., additional, Thompson, R. Houston, additional, Leibovich, Bradley C., additional, and Cheville, John C., additional

Published
2023
Full Text
View/download PDF

12. PD17-10 DISCOVERY OF A NOVEL MONOCLONAL PD-L1 ANTIBODY H1A THAT PROMOTES T-CELL MEDIATED TUMOR KILLING ACTIVITY IN RENAL CELL CARCINOMA

Author

Nabavizadeh, Reza, primary, Pessoa, Rodrigo Rodrigues, additional, An, Zesheng, additional, Gicobi, Joanina, additional, Harrington, Susan, additional, Zhang, Henan, additional, Xu, Tianxiao, additional, Hirdler, Jacob, additional, Lohse, Christine, additional, Leibovich, Bradley, additional, Dong, Haidong, additional, and Lucien, Fabrice, additional

Published
2023
Full Text
View/download PDF

15. MP04-19 IMPACT OF SURGERY ON CYTOTOXIC ACTIVITY OF PATIENT-DRIVEN CD8 T CELL

Author

Nabavizadeh, Reza, primary, Pessoa, Rodrigo Rodrigues, additional, An, Zesheng, additional, Gicobi, Joanina, additional, Harrington, Susan, additional, Zhang, Henan, additional, Xu, Tianxiao, additional, Hirdler, Jacob, additional, Lohse, Christine, additional, Leibovich, Bradley, additional, Dong, Haidong, additional, and Lucien, Fabrice, additional

Published
2023
Full Text
View/download PDF

16. Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma

Author

Gottlich, Harrison C., Nabavizadeh, Reza, Dumbrava, Mihai, Pessoa, Rodrigo Rodrigues, Mahmoud, Ahmed M., Garg, Ishita, Orme, Jacob, Costello, Brian A., Cheville, John, and Lucien, Fabrice

Abstract

Approximately 30% of renal cell carcinoma (RCC) cases present with de novo metastatic disease, while 20% to 30% of those with localized disease will develop metastases following surgical resection. Various drug classes have been investigated to treat RCC, including cytokine-based therapies, small molecule Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitors (TKIs) and antibody-based therapies. Up to 58% of patients fail to respond to primary immune checkpoint inhibitor (ICI) therapy, and nearly all initial responders experience disease progression due to the development of secondary resistance. Consequently, novel treatment options are being investigated. Review the rapidly evolving ADC therapeutic landscape in metastatic RCC including recent trials, emerging ADCs targets, and future directions for ADCs in the treatment of advanced RCC. Literature review using the MEDLINE database on important trials and presentations from the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) conferences. Key words used included “renal cell carcinoma,” “RCC,” “metastatic RCC,” “advanced RCC,” “antibody-based therapies,” “immunotherapy,” “clinical trials,” and “emerging drugs.” Specifically for review of ADCs in RCC, the following search string was used with additional review of bibliographies from retrieved papers: “((antibody drug conjugate) OR (antibody-dependent cellular cytotoxicity) OR (chimeric antigen receptor)) AND ((kidney cancer) OR (renal cell carcinoma))”. Several promising targets including MMP14, EGFR, MCT4, CA9, MET, CDH13, B7-H3, and PSMA were identified with relevant preclinical and clinical studies reviewed. While ADCs therapeutics have not shown benefit to date for renal cell carcinoma, there are ample promising candidates and targets for future research.

Published
2023
Full Text
View/download PDF

18. Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.

Author

Mahmoud, Ahmed M, Nabavizadeh, Reza, Pessoa, Rodrigo Rodrigues, Garg, Ishita, Orme, Jacob, Costello, Brian A, Cheville, John, and Lucien, Fabrice

Subjects
THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, RENAL cell carcinoma, CLINICAL trials, DRUG design, TREATMENT effectiveness, IMMUNOTHERAPY
Abstract

Renal cell carcinoma (RCC) is among the top 10 most common cancers in both men and women with an estimated 75 000 cases each year in the US. Over the last decade, the therapeutic landscape for patients with metastatic RCC has significantly evolved, with immunotherapy emerging as the new front-line therapy. Despite significant improvement in toxicity profile and survival outcomes, key concerns such as patient selection, treatment sequencing, and intrinsic and acquired resistance remain unresolved. Emerging options such as antibody-based therapeutics (eg, anti-CD70, anti-CA9, and anti-ENPP3) are being explored in clinical trials for patients with cancer resistant or refractory to current immunotherapies. Despite positive results for hematological cancers, breast cancer, and more recently bladder cancer, most antibody-based therapies failed to improve the outcomes in patients with advanced RCC. This underscores the need to understand the underlying causes of failed responses to this treatment class, which will ultimately support the rational design of more effective and tolerable treatments. In this review, we summarize the evolving landscape of RCC therapeutics and describe recent clinical trials with emerging antibody-based therapeutics. We also describe the challenges that need to be overcome for the successful creation of therapeutic antibodies for treating RCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. MP43-11 GEOGRAPHIC VARIATION OF INFECTIOUS COMPLICATIONS FOLLOWING PROSTATE BIOPSY IN THE UNITED STATES: RESULTS FROM A PRIVATELY INSURED COHORT

Author

Morrison, Jeffrey, primary, Gershman, Boris, additional, Konety, Badrinath, additional, Clark, Peter, additional, Bronsert, Michael, additional, Kutikov, Alexander, additional, Sax-Bolder, Anessa, additional, Rodriguez-Homs, Miguel, additional, Lloyd, Granville, additional, Pessoa, Rodrigo Rodrigues, additional, and Kim, Simon, additional

Published
2021
Full Text
View/download PDF

24. EDITORIAL COMMENT

Author

Cherullo, Edward E., primary, Pessoa, Rodrigo Rodrigues, additional, and Kim, Simon P., additional

Published
2020
Full Text
View/download PDF

28. Multiparametric magnetic resonance imaging (mpMRI) and PSA density for the prediction of reclassification among patients under active surveillance.

Author

Viana, Públio, primary, Horvat, Natally, additional, Pessoa, Rodrigo Rodrigues, additional, Horvat, Joao, additional, Park, Rubens, additional, Guglielmetti, Giuliano, additional, Bastos, Diogo Assed, additional, Cordeiro, Mauricio, additional, Coelho, Rafael, additional, Vargas, Hebert Alberto, additional, and Nahas, William Carlos, additional

Published
2019
Full Text
View/download PDF

31. The patient-physician interactions as seen by undergraduate medical students

Author

Kiyohara, Leandro Yoshinobu, primary, Kayano, Lilian Kakumu, additional, Kobayashi, Marcelo Luís Teixeira, additional, Alessi, Mariana Sisto, additional, Yamamoto, Marina Uemori, additional, Yunes-Filho, Paulo Roberto Miziara, additional, Pessoa, Rodrigo Rodrigues, additional, Mandelbaum, Rosana, additional, Okubo, Silvio Tanaka, additional, Watanuki, Thais, additional, and Vieira, Joaquim Edson, additional

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results